Exploring the Role of AbaComplex in Managing Dysglycemia: Insights from a Randomized, Three-Arm, Placebo-Controlled Trial

Background: Dysglycemia, characterized by abnormal blood glucose levels, is a critical factor in the development of type 2 diabetes mellitus (T2DM) and its related complications. Among the traditional approaches to managing glucose homeostasis, supplementation with natural antidiabetic molecules stands out. Among these, abscisic acid (ABA), a naturally occurring compound abundant in unripe fruits, has shown potential for improving insulin sensitivity and glucose uptake. This study examines the effects of AbaComplex (ABAc), a nutraceutical derived from thinned nectarines, on glycemic control in individuals with dysglycemia, both alone and in combination with trivalent chromium, known for its role in increasing insulin signal. Methods: A three-arm, randomized, placebo-controlled trial was conducted over 3 months with 120 participants assigned to one of three groups: ABAc alone, ABAc with trivalent chromium (ABAc-Cr), or a placebo. Results: The results showed significant improvements in glycemic control in both the ABAc and ABAc-Cr groups compared to the placebo. Specifically, glycated hemoglobin decreased by 6.6% in the ABAc group and 11.3% in the ABAc-Cr group, while the placebo group showed a 4.3% increase. Both treatment groups also exhibited significant reductions in fasting glucose, insulin levels, and HOMA-IR. Nonetheless, the SF-12 questionnaire revealed marked improvements in physical and mental health, with the ABAc group alone demonstrating slightly greater improvements in certain quality-of-life measures. Conclusions: Overall, these findings underscore the effectiveness of ABAc supplementation as a valuable approach for managing dysglycemic conditions and early-stage T2D.